Funding a 24-Month Pilot to Test Functional Restoration Beyond the Honeymoon Window
SweetFreedom is building a structured, research-driven restoration initiative designed to test a precise and consequential hypothesis:
That measurable functional recovery in established Type 1 Diabetes may be biologically achievable — even beyond the honeymoon phase — when systemic stressors are reduced in the correct sequence.
This is not a commercial program.
This is not a supplement initiative.
This is a disciplined, governance-backed attempt to test whether irreversibility has been assumed too early.
We are seeking a strategic philanthropic partner prepared to evaluate this question seriously — in person.
[ Request a Meeting ]
The Opportunity
For decades, Type 1 Diabetes research has focused on three primary strategies:
• Immune suppression
• Preservation of remaining beta-cell function
• Replacement of lost beta cells
Yet one hypothesis has not been formally tested in a structured human pilot:
Whether regeneration may fail not because it is impossible — but because it is attempted within a chronically hostile biological environment.
If restoration requires sequencing rather than suppression, the implications extend beyond a single intervention.
The 24-Month Regeneration Pilot
Population
• 8–10 adolescents and young adults (ages 16–30)
• ≥2 years since diagnosis
• Testing functional recovery beyond the honeymoon window
• Including participants with near-zero C-peptide
Primary Endpoint
Stimulated C-peptide (MMTT) measured at baseline, 12 months, and 24 months.
Secondary Measures
• Insulin requirement trends
• CGM-derived glycemic stability
• Microbiome composition shifts
• Inflammatory and immune biomarkers
• Alpha–beta hormonal signaling markers
Design Principles
Biomarker-Gated Progression
Movement between phases is conditional upon measurable biological shifts — not time-based progression.
Standard Medical Care Maintained
All participants continue conventional insulin therapy.
Independent Clinical Governance
Senior Clinical PI (Endocrinology), independent biostatistics, and safety oversight.
This pilot is designed to generate publication-grade data.
Funding Requirement
€1.15M | 24 Months
Funding enables:
• Clinical leadership and PI compensation
• Advanced laboratory testing and longitudinal monitoring
• Participant coordination and compliance infrastructure
• Scientific architecture and data analysis
• Legal, regulatory, and insurance framework
• Advisory board and governance structure
This is a capital-efficient test relative to cell-therapy or immunotherapy programs — with potentially paradigm-shifting implications.
Why This Is a High-Leverage Bet
Type 1 Diabetes research is entering a new era of technological sophistication — yet the biological question of functional reversibility in established disease remains insufficiently tested.
Most capital in the field is directed toward:
• Cell replacement platforms
• Immune modulation therapies
• Advanced delivery technologies
These approaches are high-cost, high-complexity, and long-cycle.
This initiative represents a different category of investment:
A capital-efficient, mechanism-driven pilot designed to test whether biological restoration can occur when systemic stressors are addressed in the correct sequence.
If the hypothesis fails, the field gains clarity.
If the hypothesis holds — even partially — it reorders strategic priorities across immunology, regeneration, and metabolic research.
The leverage is not in a single intervention.
The leverage is in testing whether the ceiling of ambition in established Type 1 Diabetes has been set too low.
For a philanthropic partner personally invested in a cure, this is not merely a funding decision.
It is the opportunity to enable a disciplined, publication-grade test of a question many consider too bold — yet biologically plausible.
If successful, this pilot would not only generate data.
It would mark the moment when the field shifted from managing decline to seriously testing restoration.
The legacy would not be incremental progress.
It would be the decision to test whether full recovery was possible — and to do so rigorously.
Why Philanthropy
This initiative sits between disciplines.
It does not fit neatly within traditional grant silos.
It requires mission-driven capital willing to fund a rigorous, structured test of a high-impact biological hypothesis.
Philanthropy enables courage where institutions often move slowly.
What Success Would Mean
If measurable functional recovery is observed in adolescents and young adults with established Type 1 Diabetes — even in a subset of participants — it would:
• Challenge the assumption of irreversibility
• Legitimize regeneration-first research models
• Enable integration with immunotherapy and cell therapy
• Redefine ambition ceilings in the field
The outcome would not be incremental.
It would shift the research trajectory.
Next Step
We seek a strategic conversation — not a transactional exchange.
We would value the opportunity to meet in person to present the full scientific dossier, pilot architecture, governance plan, and partnership structure.
If this question deserves to be tested seriously, we are ready.
[ Request a Meeting ]
SweetFreedom
Sequential Restoration Initiative
